Phase 1b Trial of ELX-02 to Possibly Treat Nonsense Mutations in CF and Other Diseases Begins
Sevion Therapeutics and Eloxx Pharmaceuticals announced that a first healthy subject has been dosed in a Phase 1b clinical trial assessing the safety, tolerability and drug properties of ELX-02 as a potential treatment of several genetic diseases caused by nonsense mutations, including cystic fibrosis (CF). Nonsense mutations are…